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Abstract
Over half of childhood Acute Lymphoblastic Leukemia (ALL) survivors will suffer from one or
more treatment-related medical conditions in their lifetime, many of which are known risk
factors for diabetes. This study aims to determine the prevalence and potential risk factors of
diabetes among ALL survivors from the St. Jude Lifetime Cohort (SJLIFE). We performed a
retrospective-cohort analysis of 1041 SJLIFE 10-year survivors of ALL compared to 368
controls. Risk factors associated with increased risk of type 2 diabetes (T2DM) in survivors
included: drug-induced diabetes (OR 4.98, 95% CI 2.59-9.58), obese/overweight BMI (OR 7.02,
95% CI 2.45-20.07; OR 3.26, 95% CI 1.03-10.23), and increasing age (OR 1.04, 95% CI 1.011.08). Survivors were also more likely to suffer from pre-diabetes (OR 1.33, 95% CI 1.06-1.67)
and T2DM (OR 2.03 95% CI 1.09-2.83) compared to controls, highlighting the importance of
surveillance and early interventions in SJLIFE survivors of childhood ALL.
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Introduction
Acute Lymphoblastic Leukemia (ALL) is the most common form of childhood cancer,
with over 3000 new cases occurring each year in the United States.1 Current survival rates for
childhood ALL have reached 90%, presenting a new challenge for the medical community: the
surveillance and treatment of childhood ALL survivors.1 The Childhood Cancer Survivor Study
(CCSS) and St. Jude Lifetime Cohort (SJLIFE) are both long-term follow up studies, designed to
evaluate health outcomes among aging survivors of childhood cancer.2 Research from these
studies has found that comorbidities and secondary cancers are common in childhood cancer
survivors, with over half of childhood ALL survivors suffering from one or more chronic
medical conditions in their lifetime.3 Data from the SJLIFE study has shown that survivors of
childhood ALL have an increased risk of obesity, metabolic syndrome, and hypertension, all of
which are known risk factors for diabetes.4
In the United States, the overall prevalence of diabetes has been increasing, and is
estimated to be between 12%-14% among adults.5 Individuals who suffer from diabetes are at an
increased risk for a multitude of co-existing conditions and complications, including an increased
risk of cardiovascular disease and all-cause mortality.5 The high prevalence of known diabetes
risk factors among ALL survivors potentially puts this population at an increased risk for
developing diabetes and other adverse health outcomes in the future.
Recent studies have produced conflicting information regarding an increased risk of
diabetes among ALL survivors. Reports from the SJLIFE study have shown that the prevalence
of diabetes among SJLIFE survivors is similar to that of is similar to that of age-, sex- and racematched controls.4 In contrast, ALL survivors from CCSS were found to be almost twice as
likely to be diagnosed with diabetes compared to their healthy siblings.6
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Determining whether ALL survivors are at an increased risk for developing diabetes
could allow for early interventions aimed to reduce risk and improve health outcomes within this
population. In an effort to better understand the epidemiology of diabetes within the SJLIFE
ALL survivor population, this study aims to evaluate and enumerate the prevalence of potential
risk factors for diabetes among ALL survivors enrolled in SJLIFE.
Study Aims
The primary aim of this study is to determine the prevalence of diabetes in adult survivors of
childhood ALL compared to age, gender and race matched controls from SJLIFE. Secondary
aims for this study are as follows:
1. Describe the types of diabetes experienced by ALL survivors in the SJLIFE cohort,
including: Type I Diabetes, Type II Diabetes, Pre-diabetes, Gestational Diabetes Mellitus,
and Drug-Induced Diabetes Mellitus (while undergoing treatment).
2. Evaluate the associations between treatment exposures, demographic characteristics,
health behaviors (smoking, alcohol intake, caloric/micronutrient intake, physical
activity), body habitus (percent lean mass/relative lean mass, waist to hip ratio, waist to
height ratio) and diabetes.
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Literature Review
Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia (ALL) is a form of blood cancer that affects lymphoid
cell development, resulting in the proliferation and accumulation of immature lymphoid cells. In
healthy individuals, lymphoid stem cells differentiate into lymphoblast cells in the bone marrow
before becoming mature lymphocytes. In individuals with ALL, immature lymphocytes
(lymphoblast cells) proliferate and spread from the bone marrow to extramedullary sites where
they compete successfully with normal hematopoietic cells. As the name suggests, “acute”
lymphoblastic leukemia progresses quickly and requires immediate treatment; if left untreated
the disease can be fatal within several months. Children with ALL typically present with
increased bruising, fatigue and bleeding due to thrombocytopenia and anemia.7,8 Neutropenia is
also common at ALL diagnosis, and can lead to an increased risk of infection.7,8
There are approximately 6000 new cases of ALL each year in the United States, with
over half being diagnosed in children under the age of 20 years old.7 ALL is the most common
form of childhood cancer, and accounts for 26% of all pediatric cancer cases in children less than
14 years old.9 Risk factors associated with childhood ALL include age, sex, race/ethnicity,
genetics and environmental exposures. In the United States, the incidence of ALL is highest in
children between the ages of 3 and 5 years old.7 While there is strong evidence of acquired
genetic changes leading to the development of ALL, less than 5% of cases are due to inherited
genetic syndromes.8 Males are more likely to develop childhood ALL than females, with males
accounting for 55% of all cases.7 Incidence of childhood ALL varies by race/ethnicity, with
Hispanic children having the highest incidence rates (44.9 cases per million), followed by white
children (34.2 cases per million), then black children (18.3 cases per million).9
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Treatment for childhood ALL typically begins with 4-6 weeks of remission induction
therapy, during which time glucocorticoids, vincristine, anthracyclines, and/or asparaginase are
administered.10,11 The goal of remission induction therapy is to achieve remission, at which
point the patient will begin several months of consolidation/intensification therapy followed by
2-3 years of maintenance therapy.10,12 Radiation therapy and allogeneic bone marrow transplants
are typically reserved for patients with high risk ALL or in children who have relapsed.12
Improvements in risk-directed therapy for childhood ALL has been widely successful, with the
current 5-year survival rate estimated to be 90%.9,13
While survivorship for childhood ALL is impressive, comorbidities and secondary
cancers are common among adult survivors. Chemotherapy and radiation therapy received
during ALL treatment puts survivors of childhood ALL at an increased risk for various adverse
health outcomes later in life.3 In the United States, over half of childhood ALL survivors will
suffer from one or more chronic medical conditions in their lifetime due to treatment-related
exposures 3. Data from the CCSS has shown that adult survivors of childhood ALL are at an
increased risk for muscoskeletal (OR 7.7, 95% CI, 2.8-21.3), cardiac (OR 6.9, 95% CI, 4.1-12.9),
neurological (OR 5.3, 95% CI, 3.1-11.4) and endocrine (OR 3.1, 95% CI, 2.1-4.5) conditions,
among others compared to their non-survivor siblings.3 Within the SJLIFE cohort, it has been
shown that survivors of ALL are at an increased risk for several known risk factors of diabetes,
including obesity (RR 1.47, 95%CI 1.29-1.68); metabolic syndrome (MetS) (RR 1.43, 95%CI
1.22-1.69); and hypertension (RR 2.43, 95%CI 2.06–2.86) compared to non-survivor controls.4
Diabetes Mellitus
Diabetes Mellitus (DM) is a metabolic disease characterized by the body’s inability to
regulate blood glucose levels. Individuals suffering from diabetes are at an increased risk for
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numerous health complications, including acute myocardial infarction (RR 1.8, 95% CI 1.3-2.3),
stroke (RR 1.5, 95% CI 1.1-2.0), amputation (RR 10.5, 95% CI 6.2-15), end-stage renal disease
(RR 6.1, 95% CI 5.7-6.3), and death from hyperglycemic crisis compared to non-diabetic
individuals.14 Other common diabetes-related complications include retinopathy/loss of vision,
hypertension, Charcot joints, and nerve disease, among others.15
In the United States, the overall prevalence of diabetes among adults has been increasing,
with an average of 1.7 million new cases being diagnosed each year.16 In 2014, an estimated 29
million Americans (9.3% of US population) suffered from diabetes; of those with diabetes,
approximately 8.1 million individuals were undiagnosed.16 Diabetes is the 7th leading cause of
mortality in the United States, and accounts for more deaths than AIDS and breast cancer
combined.16,17 Most diabetes diagnoses fall into one of two etiopathogenetic categories: absolute
insulin deficiency (Type 1) or a combination of insulin resistance and decreased insulin
production (Type 2).15
Type I Diabetes Mellitus (T1DM) is an autoimmune disorder that is also known as
“insulin dependent diabetes.” It is caused by the autoimmune destruction of pancreatic β-cells,
and eventually results in absolute insulin deficiency. The exact cause of T1DM is unknown;
however, environmental factors and genetics are considered to play a large role. T1DM accounts
for approximately 5% of all diagnosed diabetes cases in the United States, and has a prevalence
of 1 in 300 in adolescents under 18 years old.16,18 T1DM is more common in youth and accounts
for 85% of diabetes cases in those > 20 years old; however it can develop at any age.18
Type II Diabetes Mellitus (T2DM) is the most common form of diabetes, accounting for
90-95% of all diabetes cases in the United States.16 It is defined by the American Diabetes
Association (ADA) as individuals suffering from both relative insulin deficiency and peripheral
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insulin resistance. Risk factors associated with T2DM include: increasing age, obesity, a family
history of diabetes, and lack of physical activity. In the US, 85.2% of individuals diagnosed with
T2DM are overweight or obese, both of which can lead to insulin resistance.16 T2DM is also
more common among certain racial/ethnic groups, with American Indians, African Americans
and Hispanics, having the highest rates of diabetes, followed by Asian Americans and NonHispanic Whites.
Pre-diabetes, also known as impaired glucose tolerance (IGT) or impaired fasting glucose
(IFG), is a modifiable condition that occurs before T2DM. It is estimated that approximately 86
million Americans suffer from pre-diabetes. Individuals diagnosed with pre-diabetes have
elevated glucose levels (fasting blood glucose of 100 – 125 mg/dl), however their levels are not
high enough to be classified as T2DM. Pre-diabetes strong predictor of T2DM, with
approximately 15-30% of pre-diabetic individuals progressing to T2DM within five years.16
Lifestyle changes leading to weight loss are highly effective in patients with pre-diabetes, and
have been shown to reduce risk of T2DM by over 50%.16
Gestational Diabetes Mellitus (GDM) is a type of diabetes that occurs in women during
pregnancy and resolves post-partum. The ADA defines GDM as women diagnosed with diabetes
in the second or third trimester of pregnancy, who did not have overt diabetes prior to pregnancy.
The prevalence of GDM has been increasing in the United States and is currently estimated to be
around 14%.19 Uncontrolled GDM is dangerous for both the mother and fetus, and can result in
spontaneous abortion, fetal anomalies, preeclampsia, macrosomia, neonatal hypoglycemia,
among other risks. Post-partum women diagnosed with GDM during pregnancy are at an
increased risk of developing GDM in subsequent pregnancies, as well as developing T2DM later
in life.19
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Drug induced Diabetes Mellitus (DIDM) is a transient form of diabetes that manifests as
the result of some pharmacological treatment. DIDM has been reported in approximately 1020% of children receiving treatment for ALL; and typically occurs during the remission
induction phase of therapy when high doses of glucocorticoids and L-asparaginase are
administered.20 Age has been shown to be a strong predictor for developing DIDM, with children
≥ 10 years old being 9.6 times more likely (95% CI 5.1-17.8; P=<.001) to experience DIDM
compared to their younger counterparts.21 Trisomy 21 and central nervous system (CNS)
involvement at ALL diagnosis are also both known risk factors for DIDM in children with
ALL.21 Studies have shown no difference in remission, survival or relapse rates between
children who developed DIDM versus children who did not; however, few studies have looked at
differences in metabolic outcomes later in life.20,22,23 When comparing metabolic disturbances of
children who developed DIDM while on therapy to children who did not, it was shown that
children with a history of DIDM were more likely to develop impaired glucose tolerance (4/30
vs. 1/90, P=0.07) and other metabolic syndromes later in life, though these findings were not
statistically significant.23 Therefore, it is possible that development of DIDM during remission
induction therapy identifies individuals at risk of developing metabolic disorders later in life.
Diabetes among ALL survivors
In survivors of childhood ALL, cranial radiotherapy (CRT) has been shown to be
associated with a greater rate of increasing BMI.24 Glucocorticoids, which are prominent during
ALL treatment, are also known to produce diabetogenic effects leading to insulin resistance and
impaired β-cell function in genetically susceptible individuals.25 Both obesity and insulin
resistance are known risk factors for diabetes in the general population.16 Therefore, it is possible

7

that treatment exposures during ALL therapy could lead to an increased risk of diabetes in
survivors of childhood ALL.
Recent studies have produced conflicting information regarding the risk of diabetes
among adult survivors of childhood ALL. In 2014, Nottage et al reported that the prevalence of
overt diabetes mellitus among 784 SJLIFE ALL survivors [median age of 31.7 years, range =
18.9-59.1] was similar to that among age, sex, race matched controls. In contrast, Meacham et al
reported that childhood ALL survivors from CCSS were 1.8 times more likely (95% CI 1.2-2.6;
P=<.01) to be diagnosed with diabetes compared to their siblings. Among the CCSS cohort,
2.5% of ALL survivors suffered from DM compared to 1.7% of healthy siblings.6 However, this
increased risk was found to be primarily due to treatment exposures, specifically total body
irradiation.6
With current survival rates for childhood ALL reaching 90%, many survivors are either
approaching or well into their adulthood. Survivors of childhood ALL are known to be at an
increased risk for various treatment-related adverse health outcomes later in life, highlighting the
importance of surveillance in these survivors. It is possible that some exposures occurring during
ALL treatment lead to an increased risk of diabetes among survivors compared to the general
population. Due to the increasing number of ALL survivors and potentially modifiable risk of
diabetes, it is important to investigate both treatment-related and environmental etiologic factors
that contribute to diabetes risk within the ALL survivor population. Determining whether
survivors are at an increased risk for developing diabetes could allow for early interventions
aimed to reduce risk and improve health outcomes among survivors of childhood ALL.
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Methods
St. Jude Lifetime Study
Study Participants. The St. Jude Lifetime Cohort (SJLIFE) is an institutional review
board-approved study designed to establish a lifetime cohort of childhood cancer survivors.
Study design and details for SJLIFE have been previously published.2 Eligible participants were
survivors of childhood Acute Lymphoblastic Leukemia (ALL) who were diagnosed and treated
at SJCRH, had survived ≥10 years since diagnosis, and are currently ≥18 years of age at time of
study participation. All participants completed detailed health questionnaires as well as an oncampus visit at SJCRH, consisting of risk-based screening and diagnostic evaluations per the
recommendations of the Children’s Oncology Group Long Term Follow-Up Guidelines.26 A total
of 1041 SJLIFE study participants met the eligibility criteria for this analysis. All participants
provided written informed consent.
Non-Participants. Survivors of childhood ALL who had not completed an on-campus
evaluation were included in this analysis as non-participants. The inclusion of non-participants in
our study was to provide a comparison cohort and to elucidate any participation bias. A total of
602 non-participants were included in this analysis.
SJLIFE Controls. Control participants were recruited on SJLIFE to serve as a
comparison cohort to SJLIFE survivors. Eligible SJLIFE control participants were individuals ≥
18 years old, not currently pregnant or lactating, and either a non-first degree relative or friend of
current or past SJCRH patients. All SJLLIFE controls completed health questionnaires and an
on-campus visit that consisted of core laboratory assessments and clinical evaluations. A total of
368 SJLIFE controls were eligible for this analysis. All participants provided written informed
consent.
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Data Collection. The data used for this analysis were collected and abstracted as part of
the SJLIFE study. Medical records were abstracted for SJLIFE participants by trained
abstractors. Data abstracted from medical records included: age at ALL diagnosis, chemotherapy
treatment and dose, radiation therapy and dose, key health events, toxicities, and any secondary
malignancies. Participants also completed health questionnaires, including a total of 883 items,
assessing the following: health history, behavior and status; social and demographic factors;
psychosocial functioning; and psychosexual health. Results from baseline laboratory and
physical examinations were collected for study participants and SJLIFE controls, and included:
complete blood cell count with differential, comprehensive metabolic panel, fasting lipid panel,
measurement of insulin and hemoglobin A1c levels, and body composition measures.
Study Variables
Cancer Treatment Exposures. Participants in our study were treated with conventional
chemotherapy or hematopoietic stem cell transplant, per TOTAL therapy protocols.27
Mercaptopurine and Methotrexate treatment was evaluated categorically, as having received
treatment or having not received treatment. Cumulative doses were abstracted for the following
chemotherapeutic drugs: vincristine, Cytarabine, Aspraginase, glucocorticoids, and
Anthracycline. Dose equivalents were calculate for Asparaginase treatment (L-Asparaginase,
Pegylated Asparaginase and Erwinase Asparaginase) as the type and dose of Asparaginase
administered varied by treatment protocol.27 Dose equivalents were also calculated for
glucocorticoids, which were converted to prednisone-equivalents.28 Radiation therapy was
evaluated categorically as having received any spinal radiation or having received no spinal
radiation. Cranial Radiation Treatment (CRT) dose was evaluated as having received no CRT (0
Gy), having received 1-23 Gy or having received 24+ Gy therapy.
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Outcome Measurements. Pre-diabetes was defined per the American Diabetes
Association (ADA), as having a fasting plasma glucose level between 100 mg/dL to 125 mg/dL,
and/or HgBA1C between 5.7-6.4%. Type 2 diabetes (T2DM) was defined per the ADA, as
having a fasting plasma glucose level of ≥ 126 mg/dL (7.0 mmol/L) on two separate tests, or
HgbAlc ≥ 6.5%, or random glucose ≥ 200 mg/dL. Participants currently receiving medication for
diabetes were also classified as having T2DM. Type 1 diabetes (T1DM) was defined as
participants diagnosed with insulin-dependent diabetes. Gestational Diabetes Mellitus (GDM)
was defined per ADA guidelines, and included female participants diagnosed with diabetes
during pregnancy that was not clearly overt diabetes prior to gestation, and whose symptoms
resolved postpartum. Participants were classified as having Drug-Induced diabetes (DIDM) if
they experienced treatment-induced hyperglycemia requiring brief insulin therapy while
undergoing treatment for ALL. Classification of diabetes type for participants without a clear
diagnosis was determined by reviewing medical charts and evaluating fasting laboratory results.
Covariates. Demographic and health behavior data were collected from participant
health questionnaires and medical records by trained abstractors. Demographic factors used in
our analysis included: sex, ethnicity, marital status, household income, insurance access, and
highest level of educational attainment. Self-reported health behaviors used in our analysis
included: tobacco use, alcohol intake and level of physical activity (calculated as total Metminutes per week). Additional risk factors included in our analysis included: Body Mass Index
(BMI), categorized as underweight (<18.5 kg/m2), normal (18.5-24.9 kg/m2), overweight (2529.9 kg/m2), or obese (≥30 kg/m2), relative lean mass, and percent body fat. Relative lean mass
and percent body fat were determined by Dual energy x-ray absorptiometry (DXA) studies,
which were performed on Hologic Discovery-A unit and analyzed using APEX 3.3 software.
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Statistical Analysis
Demographic and treatment variables were characterized and compared between
participant and non-participant survivors using Chi-square tests and Fishers exact test for
categorical variables, and t-tests for continuous variables. These same methods were used to
compare demographic variables and diabetes prevalence (pre-diabetes, T2DM, GDM, T1DM,
and DIDM) between survivors and SJLIFE controls.
Generalized linear models adjusting for age, race, gender, and level of educational
attainment, were used to compare the prevalence of pre-diabetes and T2DM between survivors
and SJLIFE controls. Results were reported as odds ratios (OR) or prevalence ratios (PR), with
95% confidence intervals (95% CI). For rare outcomes, logistic regression models were used to
estimate odds ratios as an approximation to prevalence ratio estimates. For non-rare outcomes,
log binomial models were used with a log link and Poisson error structure to estimate prevalence
ratios.
Logistic regression models adjusting for age, race, gender, and level of educational
attainment, were used to evaluate associations between potential risk factors and diabetes
(T2DM, GDM, DIDM) within our study population. Potential risk factors were assessed by
bivariate analysis; those included in our analysis were determined a priori and by backwards
selection. CRT was not included in our final model for T2DM due to the fact that CRT and BMI
are on the same causal pathway for T2DM risk.29 A second logistic regression model adjusting
for BMI, in addition to the above-mentioned variables, was used to evaluate potential risk factors
associated with T2DM risk. Analyses were performed using SAS v9.4.
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Results
Cohort Characteristics
At the time of this analysis, a total of 1798 ALL survivors were potentially eligible for
enrollment on SJLIFE. Of those, 1041 individuals were eligible as participants for our analysis.
Of the remaining 757 individuals, 155 individuals died prior to participation, the remaining 602
individuals were included in our analysis as non-participants (Figure 1).
Table 1 compares demographic and treatment exposures between participants and nonparticipant survivors. There was a slightly greater proportion of males among both participant
(51%) and non-participant (57%) groups. Median age at ALL diagnosis was similar between
participant (5 years, IQR 3, 9) and non-participant (5 years, IQR 3, 9) groups. Both participant
and non-participant groups were primarily Non-Hispanic White. However, a greater proportion
of non-participants were of non-Caucasian ethnicity compared to participants (20% nonparticipants vs 13% participants).
Participants were more likely to have received cranial radiation therapy (CRT) (n=540,
53% of participants vs. n=222, 36% of non-participants) and/or spinal radiation therapy (n=84,
8% of participants vs. n=46, 8% of non-participants). Common treatment exposures between
both groups included: vincristine, cyclophosphamide, glucocorticoids, 6-mercaptopurine,
antracycline, cytarabine, methotrexate, and asparaginase. The mean cumulative dose
administered for asparaginase, anthracylines, glucocorticoids, and vincristine, was higher in nonparticipants compared to participants; with the exception of cytarabine where the mean
cumulative dose was higher in participants. There was a similar proportion of bone marrow
transplants between both participant (2%) and non-participant (3%) groups.
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Comparisons of Survivors and Controls
Characteristics and diabetes diagnoses of survivors and controls are shown in Table 2.
The median age at time of most recent interview was slightly higher in controls (34 years; IQR
28, 42) compared to survivors (33 years; IQR 27, 41). The median survival time in survivors was
28 (IQR 20, 34) years since diagnosis. Survivors were significantly more likely to be obese or
overweight compared to controls, with 73% of survivors being obese or overweight compared to
63% of controls. Compared to survivors, controls were more likely to be college graduates (53%
in controls vs. 33% in survivors, P=<0.0001) and to be female (54% in controls vs. 49% in
survivors, P=0.0857).
The prevalence for all types of diabetes (pre-diabetes, T2DM, GDM) was higher in
survivors compared to controls with the exception of T1DM. Among survivors, 27% had prediabetes and 7% had T2DM, compared to 19% and 4% of controls, respectively. Of females who
had been pregnant, the prevalence of GDM was similar between survivors (6.4%) and controls
(3.4%). The prevalence of T1DM was less than 1% in both survivor and control groups.
Compared to controls, and adjusting for age, sex, race, education and BMI, survivors
were 1.33 times more likely to have pre-diabetes (95% CI 1.06-1.67, P=0.02) and 2.03 times
more likely to have T2DM (95% CI 1.09-3.82, P=0.03; Table 3).
Risk Factors
Type 2 Diabetes Mellitus. A total of 78 (7%) survivors had been diagnosed with T2DM
(Table 2). Multivariable modeling, adjusting for sex, race, education, and BMI, identified age at
most recent interview, overweight or obese BMI, cumulative anthracyline dose and the
development of DIDM while on-therapy as predictors for T2DM among survivors (Table 4).
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Age at most recent interview was associated with a slight elevated risk of T2DM in
survivors (OR=1.04, 95% CI, 1.01-1.08; P=0.0056). Survivors who were overweight were 3.3
times more likely to have T2DM, compared to survivors who were normal/underweight (95% CI
1.03-10.23; P=0.0436). Obese survivors had the highest risk of T2DM, and were 7.02 times
more likely to have T2DM compared to survivors who were normal/underweight (95% CI 2.4520.07; P=0.0003). Neither total Met-minutes (per week/100), nor level of educational attainment
were associated with increased T2DM risk in survivors.
On treatment exposures evaluated included cumulative glucocorticoid dose (dose per
1000 mg/m2) and antrhacycline dose (per 100 mg/ m2) as well having developed DIDM.
Increased cumulative glucocorticoid dose (1000 mg/m2) was not associated with an increased
risk of T2DM in survivors (OR=0.95, 95% CI 0.906-1.004; P=0.0701). Cumulative
anthracycline dose (per 100 mg/m2) was associated with an elevated risk of T2DM (OR=1.29,
95% CI 1.04-1.61). Of the 83 survivors who developed DIDM while undergoing treatment for
ALL, 21 (25%) survivors developed T2DM later in life. Survivors who developed DIDM while
undergoing treatment for ALL were 4.98 times more likely to develop T2DM later in life,
compared to survivors who had not developed DIDM (95% CI 2.59 – 9.58; P= <.0001).
Gestational Diabetes Mellitus. Of the 514 female survivors, a total of 249 (48%) had
been pregnant at least once, of those, 16 (6%) developed GDM during pregnancy. Adjusting for
race, none of the treatment exposures included in our analysis (glucocorticoids (P=0.1211),
asparaginase (P=0.8026), anthracycline (P=0.1674)) were associated with an increased risk of
GDM (Table 5). Age at ALL diagnosis (P=0.2378) and race/ethnicity (P=0.5656), were also not
associated with an increased risk of GDM (Table 5). Participant BMI during pregnancy was not
available; therefore we could not include BMI in our model.
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Drug Induced Diabetes Mellitus. A total of 82 (8%) survivors developed DIDM while
undergoing treatment for ALL. Multivariable modeling, adjusting for sex and race, identified age
at diagnosis as a predictor for developing DIDM while on-treatment (Table 6). Age at diagnosis
of ALL was associated with an elevated risk of DIDM in survivors (OR=1.24, 95% CI 1.18-1.31;
P=<.0001). Gender, race and treatment exposures (glucocorticoids, asparaginase, anthracycline)
were not associated with an increased risk of developing DIDM.
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Discussion
In this study we evaluate the prevalence and risk factors associated with diabetes among
10-year SJLIFE ALL survivors, in an effort to better understand the epidemiology of diabetes
among this population. Of 1041 SJLIFE ALL survivors, three hundred and ninety-eight (38%)
had experienced some form of diabetes within their lifetime, compared to 23% of non-cancer
survivor controls.
To our knowledge, the prevalence of pre-diabetes among survivors of childhood ALL has
not been previously reported. Of 1041 SJLIFE ALL survivors, two hundred and seventy-seven
(27%) survivors suffered from pre-diabetes. This was significantly higher than the prevalence of
pre-diabetes reported in SJLIFE controls (19%). Survivors of childhood ALL were 1.33 times
more likely (95% CI 1.06-1.67, P=0.02) to suffer from pre-diabetes compared to SJLIFE
controls.
In contrast to previous reports from SJLIFE, we found the overt prevalence of T2DM
among SJLIFE ALL survivors to be significantly higher compared to controls.4 A total of 79
(7%) SJLIFE ALL survivors suffered from T2DM, compared to 14 (4%) SJLIFE controls
(P=0.01). Survivors were 2.03 times more likely (95% CI 1.09 – 3.82) to develop T2DM
compared to controls. These findings are similar to those reported by Meacham et al. (OR 1.8,
95% CI 1.2-1.6). Both age at interview and overweight/obese BMI were associated with an
increased risk of T2DM among survivors in our cohort. It is possible that the higher overt
prevalence of T2DM in our analysis was due increasing age, with the median age in our analysis
being 33.2 years (range= 18.43.- 62.15) compared to 31.7 (range= 18.9-59.1) at the time of the
Nottage et al. analysis.
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Anthropometric risk factors associated with an increased risk of T2DM in survivors
included age at most recent interview (OR 1.04, 95% CI 1.01-1.08), overweight BMI (OR 3.26,
95% CI 1.03-10.23) or obese BMI (OR 7.02, 95% CI 2.45-20.07). These findings are to be
expected, as age and overweight/obese BMI are well known risk factors for T2DM.16
Of exposures that occurred during ALL treatment, cumulative anthracycline dose and the
development of DIDM were associated with an increased risk of T2DM. Cumulative
glucocorticoid dose (per 1000 mg/m2) was found to have a slightly protective effect against
T2DM (OR 0.95, 95% CI 0.90-1.00; P=0.0451); however this association was lost after
adjusting for BMI (P=0.0701). This finding is similar to what was reported by Nottage et al,
where cumulative glucocorticoid dose (per 1000 mg/m2) was found to be slightly protective (RR
0.99, 95% CI 0.97-1.01) against Metabolic Syndrome in SJLIFE survivors of ALL.4 Cumulative
anthracycline dose (per 100 mg/m2) was associated with an elevated risk of T2DM (OR 1.29,
95% CI 1.04-1.61). While the association between anthracyclines and diabetes has not been
previously evaluated, anthracyclines have been shown to increase risk of elevated glucose levels
(RR 1.24, 95% CI 0.95-1.61) within this cohort.4
Few studies have investigated the association between DIDM and T2DM risk among
survivors of childhood ALL. Yeshayahu et al. reported the rate of impaired glucose tolerance
among survivors of childhood ALL as being four times higher in those who developed DIDM
compared to those who did not, however this findings did not reach statistical significance.23 Our
analysis found that SJLIFE ALL survivors who developed DIDM while on-therapy were 4.98
times more likely (95% CI 2.59-9.58) to be diagnosed with T2DM compared to survivors who
did not develop DIDM. This increased risk remained the same both when adjusting and not
adjusting for BMI. To our knowledge, this finding is unique to our study and potentially
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identifies a subgroup of individuals who have an elevated risk of developing diabetes and other
adverse health outcomes later in life.
Previous studies have reported the prevalence of DIDM in children undergoing treatment
for ALL to be between 10 to 20%.20,30 Among SJLIFE ALL survivors, 83 (8%) survivors
developed DIDM while undergoing treatment for ALL. It is possible that the lower prevalence of
DIDM in our cohort is due to our study consisting of 10-year survivors, whereas the prevalence
reported in other studies was determined in patients undergoing ALL treatment. It is also
important to note that our definition of DIDM may have resulted in milder cases, where
treatment was not administered, being excluded in our analysis, whereas other studies may have
included these cases. As a result, our analysis captured individuals who experienced more
serious DIDM where brief insulin therapy was required, as opposed to all individuals who
developed any level of DIDM. Age at ALL diagnoses was associated with an elevated risk of
developing DIDM during treatment (OR 1.24, 95% CI 1.18-1.31) in SJLIFE ALL survivors. This
finding is consistent with reports from previous studies.20,23,30
While our findings show an increased risk of T2DM in survivors who experienced
DIDM, further studies are needed to evaluate the cause of this increased risk. It is possible that
the development of DIDM in some patients unmasks an underlying predisposition leading to an
increased risk of T2DM, similar to the increased risk of T2DM in women who develop GDM
while pregnant. Since diabetes is highly associated with obesity, it would be beneficial to
evaluate the association between BMI during treatment and DIDM risk.
The prevalence of GDM among females who had experienced one or more pregnancies
was similar between control and survivor groups (3% controls vs. 6% survivors). Of the
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demographic and treatment exposures included in our analysis, none were significantly
associated with an increased risk of GDM in female survivors who had been pregnant.
Limitations
It is worth noting the findings from this study should be considered within the context of
study limitations. It is possible the results of our analysis were influenced by selection bias due
to the 36% participation rate. It is possible that survivors who participated in on-campus
evaluations may have differed in health status compared to non-participants; however, the
demographic differences between participants and non-participants have been previously
investigated and were found to be unsubstantial.31 Survivors were only recruited from one
institution, St. Jude Children’s Research Hospital, which limits the widespread applicability of
our findings. In our model for GDM we were unable to include patient BMI at time of GDM
diagnosis, as this information was not available at the time of our analysis. Due to the
relationship between high BMI and insulin resistance, it would be of interest to include patient
BMI at GDM diagnosis in a future analysis. It is also possible that our sample size of survivors
who developed GDM (n=16) was too small to detect any associations between exposures and
GDM risk. The use of standardized follow-up medical assessments in SJLIFE has allowed for
the continued collection of objective measures such as height, weight, percent body fat, among
others, in SJLIFE ALL survivors. However, some self-reported measures such as smoking,
alcohol intake, total met-minutes per week, are known risk factors for diabetes; as a result, these
measures may have been over- or under- estimated in our population.
Conclusion
Adults diagnosed with diabetes are at an increased risk for numerous chronic health
conditions, ranging from metabolic syndrome to cardiovascular disease.5 Among SJLIFE
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survivors of childhood ALL, there is a high prevalence of both pre-diabetes and T2DM, 27% and
7%, compared to controls, 19% and 4%, respectively. Survivors are also at a 33% increased risk
for pre-diabetes and over 100% increased risk of developing T2DM compared to controls. Our
findings show that age, obese/overweight BMI and a diagnosis of DIDM while on treatment, are
all predictors of T2DM in survivors of childhood ALL. As the survival rate for childhood ALL
continues to improve, it is important to investigate late-effect health outcomes in this aging
population. The high prevalence and increased risk of diabetes among SJLIFE ALL survivors,
combined with the potentially modifiable risk of diabetes, underscores the importance of
surveillance and early interventions among survivors. Therefore, it is important to continue
investigating treatment-related factors and other factors associated with an increased risk of
adverse health outcomes, in a continued effort to improve the treatment of childhood ALL.
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Potentially Eligible 10 Year Cancer Survivor through June 30, 2016
N=6044

Potentially eligible for
assessment
N=6044

Potentially eligible without ALL
N=4246

Potentially eligible with
ALL
N=1798
Dead prior to
participation
N=155

Alive, not yet recruited (N=72)
Consented only (N=19)
Survey only (N=68)
Interested, participation pending
(N=207)
Non-participants (N=236)
Non-participants (N=261)

Campus visit with ALL
N=1041

Figure 1. Consort diagram of 10 year survivors of Acute Lymphoblastic Leukemia (ALL)
eligible as participants in our analysis
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Table 1. Characteristics of SJLIFE participants and non-participants
Characteristics

Participants
N (%)

Non-Participants
N (%)

P-value
Sex
Female
510 (49)
260 (43)
0.0232
Male
531 (51)
342 (57)
Race
Non-Hispanic White
903 (87)
482 (80)
0.0004
Non-Hispanic Black
94 (9)
66 (11)
Hispanic
23 (2)
20 (3)
Asian
3 (0)
4 (1)
Other
18 (2)
30 (5)
Spinal radiation
No
957 (92)
556 (92)
0.7568
Yes
84 (8)
46 (8)
Cranial Radiation Dose
0 Gy
476 (47)
350 (58)
<.0001
1-23 Gy
234 (23)
95 (15)
24+ Gy
306 (30)
127 (21)
Bone Marrow Transplant
No
1016 (98)
583 (97)
0.3613
Yes
25 (2)
19 (3)
6-Mercaptopurine
No
8 (1)
5 (1)
1.0000**
Yes
1033 (99)
597 (99)
Methotrexate: IT or Oral
No
1 (0)
2 (0)
0.5583**
Yes
1049 (100)
600 (100)
At ALL diagnosis (years)
Mean (SD)
7 (4)
7 (5)
0.8700*
Median (IQR)
5 (3, 9)
5 (3, 9)
Survival Time (years since diagnosis)
Mean (SD)
27
.
.
Median (IQR)
28 (20, 34)
.
Cumulative Vincrinstine dose (mg/m2)
Mean (SD)
37 (28)
39 (27)
0.2066
Median (IQR)
44 (6, 58)
46 (7, 59)
Cumulative Cytarabine dose (mg/m2)
Mean (SD)
6492 (5030)
6134 (4923)
0.2113*
Median (IQR)
5254 (2094, 10662)
4915 (1899, 10102)
Cumulative Glucocorticoids dose (mg/m2)
Mean (SD)
7436 (5692)
7637 (5438)
0.4859*
Median (IQR)
9520 (1120, 10830)
9560 (1160, 11925)
Cumulative Anthracycline dose (mg/m2)
Mean (SD)
124 (89)
127 (79)
0.5913*
Median (IQR)
102 (55, 151)
103 (77, 156)
Cumulative Asparaginase dose (mg/m2)
Mean (SD)
5879 (6505)
8158 (9761)
<.0001*
Median (IQR)
3534 (2060, 6265)
4553 (2497, 10304)
Notes: Differences between participants and non-participants were examined using Chi-Square tests. T-tests were
used to examine continuous variables, marked with ‘*’. Fishers exact tests were used to compare variables with
small sample size, marked with ‘**’. SD, standard deviation, IQR; interquartile range; Gy, Gray; IT, intrathecal
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Table 2. Characteristics of SJLIFE survivors and controls
SJLIFE ALL Survivors
N (%)

SJLIFE controls
N (%)

34 (9)
33 (27, 41)

35 (10)
34 (28, 42)

0.0223*

510 (49)
531 (51)

200 (54)
168 (46)

0.0773

903 (87)
94 (9)

310 (84)
23 (6)

0.0002

2: Hispanic

23 (2)

10 (3)

3: Asian
4: Other
Education
1: <College Graduate
2: College Graduate

3 (1)
18 (2)

3 (1)
22 (6)

670 (64)
340 (33)

167 (45)
195 (53)

31 (3)

4 (1)

17 (2)

12 (3)

2: Normal
3: Over weight

264 (25)
287 (28)

126 (34)
102 (28)

4: Obese
No Diabetes
0: No
1: Yes
Pre-Diabetes
0: No
1: Yes

473 (45)

128 (35)

396 (38)
645 (62)

85 (23)
283 (77)

<.0001

765 (73)
276 (27)

300 (81)
68 (19)

0.0020

1038 (100)

365 (99)

0.1871**

3 (0)

3 (1)

963 (93)
78 (7)

354 (96)
14 (4)

0.0138

233 (94)
16 (6)

115 (97)
4 (3)

0.2837

Characteristics
Age At most recent interview
Mean (SD)
Median (IQR)
Sex
Female
Male
Race
0: Non-Hispanic White
1: Non-Hispanic Black

3: Other
Body Mass Index (BMI)
1: Underweight

Type I Diabetes
0: No
1: Yes
Type 2 Diabetes
0: No
1: Yes
Gestational Diabetes Mellitus
0: No
1: Yes

<.0001

0.0003

.

Drug Induced Diabetes Mellitus
0: No

P-value

959 (92)

.

1: Yes
82 (8)
.
Notes: Differences between participants and controls were examined using Chi-Square tests. T-tests were used to
examine continuous variables, marked with ‘*’. Fishers exact tests were used to compare variables with small
sample size, marked with ‘**’. SD, standard deviation, IQR; interquartile range
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Table 3. Comparing the Prevalence of Pre-diabetes and Type 2 Diabetes between SJLIFE ALL survivors and controls
Pre-diabetes

Type 2 Diabetes*

(N=344)

(N=92)

Adjusted for BMI

Not adjusted for BMI

Adjusted for BMI

Not adjusted for BMI

%

PR

95%
P-value
CI

PR

95%
CI

P-value

%

PR

95%
CI

P-value

PR

95%
CI

P-value

Survivors
(N=1041)

27

1.33

1.051.67

0.02

1.41

1.121.78

0.004

7

2.03

1.093.81

0.03

2.34

1.264.36

0.007

Controls
(N=368)

19

Ref

.

.

.

.

.

4

Ref

.

.

.

.

.

Notes: Logistic regression model was used to estimate odds ratio as an approximation to PR for rare outcomes (<10%), marked with ‘*’. PR, Prevalence Ratio;
95% CI, 95% confidence interval; BMI, Body Mass Index; P, P-value; %, % of those with outcome; Ref; referent group
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Table 4. Risk Factors for Type 2 Diabetes in adult survivors of childhood ALL
Adjusted for BMI

Characteristics

Not Adjusted for BMI

OR

95% CI

P-value

OR

95% CI

P-value

1.04

1.01 - 1.08

0.0056

1.05

1.02 - 1.08

0.0005

Male (referent)

1.00

.

.

1.00

.

.

Female

1.11

0.67 - 1.85

0.6904

1.07

0.65 - 1.77

0.7904

Non-Hispanic White (referent)

1.00

.

.

1.00

.

.

Other

1.88

0.91 - 3.89

0.0881

1.82

0.90 – 3.68

0.0968

< College Graduate (referent)

1.00

.

.

1.00

.

.

College Graduate

0.66

0.37 - 1.18

0.1577

0.60

0.33 – 1.06

0.0795

Other

2.81

0.99 - 7.96

0.0523

2.65

0.96 – 7.29

0.0590

Underweight/Normal (referent)

1.00

.

.

.

.

.

Overweight

3.26

1.03 - 10.23

0.0436

.

.

.

Obese

7.02

2.45 - 20.07

0.0003

.

.

.

0.99

0.97 - 1.00

0.1088

0.99

0.97 -1.00

0.0760

0.95

0.91 - 1.00

0.0701

0.95

0.90 – 1.00

0.0451

1.29

1.04 - 1.61

0.0217

1.25

1.01 - 1.55

0.0403

Age
Age at most recent interview
Gender

Race

Education

BMI

Physical Activity
Total Met-minutes per week per 100
On Treatment Exposures
Glucocorticoid dose per 1000 mg/m2
Anthracycline dose per 100 mg/m

2

Drug Induced Diabetes Mellitus
4.98
2.59 - 9.58
<.0001 4.98 2.64 – 9.39
<.0001
Notes: OR, Odds Ratio; 95% CI, 95% confidence interval; BMI, Body Mass Index; ALL, Acute Lymphoblastic
Leukemia
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Table 5. Risk Factors for Gestational Diabetes in female adult survivors of childhood ALL
Characteristics
Age
Age at ALL diagnosis
Race
Non-Hispanic White (referent)
Other
Chemotherapy
Glucocorticoid dose per 1000 mg/m2
Anthracycline dose per 100 mg/m2
Asparaginase dose per 1000 mg/ m2

OR

95% CI

P-value

1.06

0.94 - 1.21

0.3580

1.00
0.51

.
0.06 - 4.45

.
0.5436

0.91
1.36
1.02

0.80 - 1.03
0.77 - 2.41
0.88 - 1.19

0.1253
0.2924
0.8026

Notes: OR, Odds Ratio; 95% CI, 95% confidence interval; ALL, Acute Lymphoblastic Leukemia
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Table 6. Risk Factors for Drug-Induced Diabetes while undergoing treatment for childhood ALL
Characteristics
Age
Age at ALL diagnosis
Gender
Male (referent)
Female
Race
Non-Hispanic White (referent)
Other
Chemotherapy
Glucocorticoid dose per 1000 mg/ m2
Anthracycline dose per 100 mg/m2
Asparaginase dose per 1000 mg/ m2

OR

95% CI

P-value

1.24

1.18 - 1.31

<.0001

1.00
0.79

.
0.49 - 1.29

.
0.3454

1.00
1.69

.
0.91 - 3.11

.
0.0944

1.03
0.72
1.02

0.98 - 1.08
0.49 - 1.07
0.98 - 1.07

0.2388
0.1025
0.2538

Notes: OR, Odds Ratio; 95% CI, 95% confidence interval; ALL, Acute Lymphoblastic Leukemia
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